Unicycive Therapeutics, Inc. (UNCY) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company focused on kidney disease. Its primary product candidates are oxylanthanum carbonate (OLC) for hyperphosphatemia in chronic kidney disease (CKD) patients and UNI-494 for acute kidney injury (AKI). The company is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(12,823) | $570 (Income) |
| Operating Expenses | $8,437 | $7,989 |
| Cash and Cash Equivalents | $37,371 | $29,198 |
| Marketable Securities | $17,215 | $12,071 |
| Total Current Assets | $63,545 | $48,961 |
| Warrant Liability | $21,695 | $16,915 |
| Accumulated Deficit | $(140,648) | $(127,825) |
Material Changes vs. Prior Period
- Net Loss vs. Income: The company reported a net loss of $12.8 million in Q1 2026, compared to a net income of $0.6 million in Q1 2025. This reversal was primarily driven by a $13.1 million swing in the fair value of warrant liabilities (from an $8.3 million gain in 2025 to a $4.8 million expense in 2026).
- Operating Expenses: Total operating expenses increased by 6% to $8.4 million. General and administrative (G&A) expenses rose 17% to $6.8 million due to higher consulting and professional fees, while Research and Development (R&D) expenses decreased 26% to $1.6 million.
- Liquidity Position: Cash and cash equivalents increased by $8.2 million to $37.4 million, and total current assets grew to $63.5 million. This improvement was fueled by financing activities, specifically the sale of common stock under a sales agreement with Guggenheim Securities, which generated approximately $19.6 million in net proceeds during the quarter.
- Warrant Liability: The warrant liability increased by $4.8 million to $21.7 million, reflecting changes in fair value inputs, including the probability of achieving technical milestones and regulatory approvals.
Outlook, Risks, and Management Commentary
- Regulatory Status: The FDA accepted the resubmission of the New Drug Application (NDA) for OLC in January 2026, setting a PDUFA target action date of June 29, 2026. The resubmission addressed a single deficiency regarding a third-party manufacturing vendor's compliance status.
- Liquidity and Capital Needs: Management believes current resources are sufficient to fund operations for at least 12 months. However, the company expects to incur substantial additional losses and will require further capital to complete clinical trials and commercialization efforts.
- Legal Proceedings: The company is facing a putative shareholder class action lawsuit (Elkhodari v. Unicycive Therapeutics, Inc.) and related derivative actions alleging misrepresentations regarding OLC manufacturing and NDA approval prospects. The company intends to vigorously defend these claims but notes that defense costs could be material.
- Corporate Changes: On April 6, 2026, Director Gaurav Aggarwal, M.D., resigned from the Board of Directors. The resignation was not related to any disagreement with the company.
Investor Verification Checklist
- Warrant Liability Volatility: Verify the sensitivity of the $21.7 million warrant liability to changes in the probability of FDA approval and commercial milestones, as this significantly impacts reported net income/loss.
- Manufacturing Compliance: Confirm the status of the third-party manufacturing vendor (Shilpa Medicare Ltd) regarding the compliance deficiency that led to the previous Complete Response Letter (CRL).
- Legal Exposure: Monitor the progress of the securities class action and derivative lawsuits, specifically the court's ruling on the motion to dismiss filed in March 2026.
- Cash Burn Rate: Assess the sustainability of the current cash position ($37.4 million) against the projected burn rate required to reach the June 2026 PDUFA date and potential commercialization.
- Equity Dilution: Review the terms of the ongoing sales agreement with Guggenheim Securities and the potential dilution from outstanding warrants and convertible preferred stock.